The pharmaceutical industry is entering the first quarter earnings season on Apr. 14 with a focus on mergers and acquisitions, as recent deals and easing regulatory pressures shape expectations for company performance.
This period is significant as analysts and investors seek clarity on business development strategies following a series of high-value transactions across the sector. Additional topics of interest include personnel changes at the Food and Drug Administration, drug pricing developments, upcoming midterm elections, and tariffs.
Despite broader economic struggles tied to geopolitical tensions such as the U.S.-Iran war, biopharma has been described by BMO Capital Markets as a relative safe haven. BMO noted that while large-cap companies like Gilead Sciences, Merck & Co., Pfizer Inc., and Bristol Myers Squibb have provided stability for investors, first-quarter results could bring volatility as estimates are refined for the fiscal year. Historically, sales slow in the first quarter due to insurance resets but typically recover throughout the rest of the year according to multiple analyst firms including Truist.
Recent M&A activity has accelerated in late Q1 with major deals involving Eli Lilly's acquisition of Centessa Pharmaceuticals, Merck's purchase of Terns Pharmaceuticals, and Biogen's deal for Apellis Pharmaceuticals. In total, about $46.8 billion was spent across 19 transactions during this period. Analysts attribute this uptick to greater clarity around tariffs—despite new White House announcements—and ongoing efforts by companies to address patent expirations through portfolio rationalization.
Earnings calls from major players are expected to provide updates on product launches and strategic direction. Johnson & Johnson will discuss immunology drug Tremfya’s growth along with its pipeline after recent acquisitions; Novo Nordisk will report initial revenue from its oral GLP-1 medicine Wegovy; Eli Lilly has launched Foundayo into an increasingly competitive weight loss market; Amgen faces questions about its obesity therapy MariTide; Pfizer anticipates data from a key Phase 3 trial acquired via Metsera; while Merck manages integration challenges following its purchase of Terns Pharmaceuticals at a reduced valuation after reviewing trial data.
Gilead Sciences recently completed three deals totaling nearly $15 billion but emphasized that these do not indicate a shift in strategy or urgency—rather they reflect coincidental timing in finding suitable partners. For smaller biotechnology firms, analysts suggest that sustained M&A momentum may encourage more exits from private markets or help reopen initial public offering opportunities over coming quarters.
